Curated News
By: NewsRamp Editorial Staff
August 14, 2026
Helix BioPharma Announces Board Changes: CEO Joins, Grabski Resigns
TLDR
- Helix BioPharma strengthens board with CEO Thomas Mehrling, enhancing leadership for clinical progress and potential investor confidence.
- Helix BioPharma appoints CEO Thomas Mehrling as director following Janusz Grabski's resignation, aligning with governance needs and acquisition terms.
- Helix BioPharma's board changes aim to advance cancer therapies for underserved patients, improving future treatment options.
- Helix BioPharma's CEO Thomas Mehrling joins the board after the resignation of Janusz Grabski, effective immediately.
Impact - Why it Matters
This news matters because board composition changes at a clinical-stage oncology company can signal shifts in strategic direction and governance, potentially affecting investor confidence and the company's ability to advance its promising pipeline. With CEO Thomas Mehrling joining the board, there is likely a stronger alignment between management and oversight, which could streamline decision-making and bolster execution of clinical development plans. For patients, this may translate into faster progress for potential treatments like L-DOS47 for non-small cell lung cancer, which addresses an unmet medical need. Investors should note the board's commitment to meeting evolving capital markets requirements, which could enhance the company's financial stability and growth prospects.
Summary
VANCOUVER, BRITISH COLUMBIA - August 14, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, today announced changes to its Board of Directors (the “Board”), effective immediately.
Mr. Janusz Grabski has resigned from Helix’s Board, with immediate effect. Concurrently, the Board has formally appointed Thomas Mehrling, M.D., Ph.D., Helix’s Chief Executive Officer, as a director of the Company, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix’s 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
Collectively, these changes are intended to ensure that the Board continues to meet Helix’s evolving governance and capital markets requirements and has the composition and experience needed to support the Company’s clinical development and broader corporate objectives.
The Board would like to thank Mr. Grabski for his service and contributions to Helix and wishes him every success in his future endeavors.
About Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
Helix BioPharma’s common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, please visit https://www.helixbiopharma.com/
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Helix BioPharma Announces Board Changes: CEO Joins, Grabski Resigns
